Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Common Equity (2022 - 2025)

Dr Reddys Laboratories has reported Common Equity over the past 4 years, most recently at $3.8 billion for Q1 2025.

  • For Q1 2025, Common Equity rose 13.96% year-over-year to $3.8 billion; the TTM value through Mar 2025 reached $3.8 billion, up 13.96%, while the annual FY2025 figure was $3.9 billion, 15.16% up from the prior year.
  • Common Equity for Q1 2025 was $3.8 billion at Dr Reddys Laboratories, up from $3.4 billion in the prior quarter.
  • Over five years, Common Equity peaked at $3.8 billion in Q1 2025 and troughed at $2.5 billion in Q1 2022.
  • A 4-year average of $3.1 billion and a median of $3.1 billion in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: rose 10.9% in 2023 and later grew 20.22% in 2024.
  • Year by year, Common Equity stood at $2.5 billion in 2022, then increased by 10.9% to $2.8 billion in 2023, then grew by 20.22% to $3.4 billion in 2024, then increased by 13.96% to $3.8 billion in 2025.
  • Business Quant data shows Common Equity for RDY at $3.8 billion in Q1 2025, $3.4 billion in Q1 2024, and $2.8 billion in Q1 2023.